A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes (Q34421851)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

type-1 diabetes

0 references

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

1

object named as

Kevan C Herold

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jeffrey A Bluestone

10

object named as

Jeffrey A Bluestone

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Stephen E Gitelman

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Umesh Masharani

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

William Hagopian

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Brygida Bisikirska

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

David Donaldson

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Kristina Rother

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Beverly Diamond

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

David M Harlan

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1763-1769

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Use of CD3 antibodies in transplantation and autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Factors associated with early remission of type I diabetes in children treated with cyclosporine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

Characterization of seven C-peptide antisera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

6 July 2018

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

27 October 2018

Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

27 October 2018

In vitro characterization of five humanized OKT3 effector function variant antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

27 October 2018

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

27 October 2018

Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5315015

27 October 2018

A novel high-throughput method for accurate, rapid, and economical measurement of multiple type 1 diabetes autoantibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15919798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/15919798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15919798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin

1 reference

https://pubmed.ncbi.nlm.nih.gov/15919798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humoral immune response against OKT3

1 reference

https://pubmed.ncbi.nlm.nih.gov/15919798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15919798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/15919798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/15919798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/15919798

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2337/DIABETES.54.6.1763

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

release_67vovvbinjbrhn5j64nsl5ro5e

1 reference

https://api.fatcat.wiki/v0/release/67vovvbinjbrhn5j64nsl5ro5e

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34421851&oldid=2210387247"